$MRNA surged 108% in premarket trading after delivering what could be a defining milestone for mRNA beyond vaccines. Moderna and Merck's personalized mRNA cancer therapy met both the primary RFS endpoint and key secondary DMFS endpoint in Phase 3 melanoma, showing statistically significant and clinically meaningful improvements over Keytruda alone. This marks the first positive Phase 3 readout for an individualized neoantigen therapy — and for any mRNA-based cancer therapy. Full data are still to come, with Moderna and Merck now preparing to engage regulators on potential filings. → Not investment advice. For informational purposes only.